HOME >> MEDICINE >> NEWS
NIAID begins enrolling volunteers for novel HIV vaccine study

A large clinical trial of a novel HIV vaccine has begun enrolling volunteers at sites in North America, South America, the Caribbean and Australia. Organizers are seeking 1,500 participants.

The trial is co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the pharmaceutical company Merck & Co. Inc. Merck developed the experimental vaccine to stimulate HIV-specific cellular immunity, which prompts the body to produce T cells that kill HIV-infected cells. In previous smaller trials, this vaccine was found to be safe and to induce cellular immune responses against HIV in more than half of volunteers.

"This new study is the first time we have used such a large sample of people to test whether a vaccine that stimulates cellular immunity alone either blocks HIV infection, decreases the level of HIV early in infection or both," says Anthony S. Fauci, M.D., director of NIAID.

This proof-of-concept trial is designed to yield vital information on the potential efficacy of cellular immunity against HIV, although it is not expected to provide enough data to support immediate licensing of the vaccine for public use, says Margaret (Peggy) Johnston, Ph.D., who oversees HIV vaccine research at NIAID's Division of AIDS.

The Merck vaccine contains a weakened adenovirus that serves as a carrier for three subtype B HIV genes. Subtype B is the most prevalent HIV subtype in the regions of the study sites. Adenoviruses are among the main causes of upper respiratory tract ailments such as the common cold. Because the vaccine contains only three HIV genes housed in a weakened adenovirus, study participants cannot become infected with HIV or get a respiratory infection from the vaccine.

"If this study finds that the vaccine can prevent or control infection, we will work with Merck to evaluate the vaccine in a larger number of volunteers," adds Dr. Johnston. "We will al
'"/>

Contact: NIAID News Office
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
24-Jan-2005


Page: 1 2

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID-sponsored clinical trial aims to boost flu vaccine supply
4. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
5. NIAID launches influenza genome sequencing project
6. NIAID launches program to improve medical tools against emerging infectious diseases
7. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
8. NIAID rotavirus vaccine licensed for commercialization
9. Second NIAID SARS vaccine candidate helps mice fend off SARS
10. NIAID vaccine protects against SARS virus infection in mice
11. NIAID Ebola vaccine enters human trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... ... The pandemic and topsy-turvy economic outlook continues to put financial strain on many of us, ... the fat from our monthly expenses and put more into savings, if possible. , “That’s ... a financial safety net in place in case something were to happen to you,” says ...
(Date:8/31/2020)... NEW HAVEN, Conn. (PRWEB) , ... August 31, ... ... a medical device intended to improve outcomes for patients with advanced heart failure, ... Innovation Research (SBIR) grant in the amount of $555,358 from the National Heart, ...
(Date:8/28/2020)... ... August 28, 2020 , ... The ... a customized Lighthouse Health & Wellness mobile app and web-portal. NCPCV received a ... Solutions Foundation awards grants each year to organizations, such as Destination Imagination, which ...
(Date:8/28/2020)... , ... August 28, 2020 , ... ... observations that strongly suggest that obese individuals are at an increased risk of ... any more likely to catch COVID-19; however, because the same organ systems that ...
(Date:8/26/2020)... ... August 26, 2020 , ... Smile ... upcoming Global Inclusion Online Forum, leading a session entitled, “A CEO Guide for ... of this magnitude designed to bring together the world’s leading diversity and inclusion ...
Breaking Medicine News(10 mins):
(Date:9/3/2020)... ... 2020 , ... Q&J Face Masks announced today that the ... engineering lab, conducted tests on Q&J’s personal face mask that indicated the Q&J ... masks. Q&J face masks have both mechanical filtering and electrostatic filtering which are ...
(Date:9/2/2020)... (PRWEB) , ... September 02, 2020 , ... U.S. ... Jonathan Lee . Dr. Lee will work at Bethesda Dermatopathology Lab. ... his B.A. from the University of California, Berkley. He went on to receive his ...
(Date:9/1/2020)... ... ... Breast and ovarian cancers are common diseases that affect many women. According to ... per year) and 10% of ovarian cancers (about 2,000 women per year) result from ... the Women’s Excellence Genetic Testing Program. , Dr. Jonathan Zaidan, MD, FACOG, President of ...
Breaking Medicine Technology:
Cached News: